Table 2.
Summary of voltage gated (Kv) and the 2-pore domain (K2P) potassium channel families, activators and inhibitors
| KV channels (42 isoforms & 12 subfamilies) |
K2P channels (15 isoforms) |
||
|---|---|---|---|
| HGCN | IUPHAR | HGCN | IUPHAR |
| KCNA1–A0 | KV1.1–KV 1,10 | KCNK1 | K2P1.1 |
| KCNB1–B2 | KV2.1 & KV2.2 | KCNK2 | K2P2.1 |
| KCNC1–C4 | KV3.1–KV3.4 | KCNK3 | K2P3.1 |
| KCND1–D3 | KV4.1–KV4.3 | KCNK4 | K2P4.1 |
| KCNF1 | KV5.1 | KCNK5 | K2P5.1 |
| KCNG1–G4 | KV6.1–KV6.4 | KCNK6 | K2P6.1 |
| KCNQ1–Q5 | KV7.1–KV7.5 | KCNK7 | K2P7.1 |
| KCNV1& V2 | KV8.1 & KV8.2 | KCNK9 | K2P9.1 |
| KCNS1–3 | KV9.1–KV9.3 | KCNK10 | K2P10.1 |
| KCNH1 & H5 | KV10.1 & KV10.2 | KCNK12 | K2P12.1 |
| KCNH2, H6, and H7 | KV11.1–KV11.3 | KCNK13 | K2P13.1 |
| KCNH8, H3, and H4 | KV12.1–KV12.3 | KCNK15 | K2P15.1 |
| KCNK16 | K2P16.1 | ||
| KCNK17 | K2P17.1 | ||
| KCNK18 | K2P18.1 | ||
| Channel opener for KV: Correolide (KV1.5), Stromatoxin-1 (KV2.1), Flupirtine (KV7) PD118057, NS1643 (KCNH) | Channel opener for K2P: Arachidonic acid (TREK-1), volatile anesthetics (isoflurane) | ||
| Channel blocker for KV: 4-AP (KV), phrixotoxin-2 (KV4), Linopirdine (KV7), dofetilide, E4031, Be-KM1 (KCNH) | Channel blocker for K2P: Fluphenazine, L-methionine (TREK-1), SSRI, antipsychotics (haloperidol) | ||
The table is adopted from reference [11].